ESMO: Regeneron Mounts Credible Challenge To Keytruda With Libtayo Survival Data In NSCLC
Claims ‘Best-In-Class’ Status
Executive Summary
Libtayo looks to have surpassed all competitors but Merck’s Keytruda in first line NSCLC, but the unique ‘all-comers’ trial design of EMPOWER-Lung-3 complicates the picture.